Quest Diagnostics (DGX) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.35, $0.02 better than the analyst estimate of $2.33. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.39 billion.

GUIDANCE:

Quest Diagnostics sees FY2024 EPS of $8.80-$9.00, versus the consensus of $8.86.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy